Syndax Pharmaceuticals Inc SNDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-7.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $172.4M | -$285.4M | — | -$323.2M | $64.6M |
| 2024 | $23.7M | -$318.8M | — | -$274.9M | $288.1M |
| 2023 | $0 | -$209.4M | — | -$160.6M | $554.2M |
| 2022 | $0 | -$149.3M | — | -$133.7M | $467.4M |
| 2021 | $139.7M | $24.9M | — | $29.0M | $408.4M |
| 2020 | $1.5M | -$73.2M | — | -$71.3M | $252.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Botwood Nicholas A.J. | Head of R&D, CMO | 2026-06-12 | Sell | 31,235 | $18.14 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 2026-06-12 | Option exercise | 31,235 | $13.82 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 2026-06-11 | Option exercise | 22,515 | $13.82 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 2026-06-11 | Sell | 34,280 | $18.00 |
| Goldan Keith A. | Chief Financial Officer | 2026-06-01 | Sell | 1,177 | $18.99 |
| Metzger Michael A | Chief Executive Officer | 2026-06-01 | Sell | 6,847 | $18.99 |
| Goldan Keith A. | Chief Financial Officer | 2026-02-09 | Sell | 3,410 | $21.03 |
| Metzger Michael A | Chief Executive Officer | 2026-02-09 | Sell | 17,159 | $21.03 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.54 (distress)
- Working capital / assets 0.77
- Retained earnings / assets -2.844
- EBIT / assets -0.516
- Equity / liabilities 0.139
Source: SEC EDGAR filings · CIK 0001395937 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.